Pharmacokinetics and Tolerability of Amikacin Administered as BAY41-6551 Aerosol in Mechanically Ventilated Patients with Gram-Negative Pneumonia and Acute Renal Failure

BAY41-6551, a drug-device combination in development for adjunctive treatment of Gram-negative pneumonia in intubated and mechanically ventilated patients, consists of amikacin formulated for inhalation coupled with the Pulmonary Drug Delivery System (PDDS) Clinical aerosol delivery platform. Given...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of aerosol medicine 2011-08, Vol.24 (4), p.183-190
Hauptverfasser:	LUYT, Charles-Edouard, ELDON, Michael A, STASS, Heino, GRIBBEN, Dennis, CORKERY, Kevin, CHASTRE, Jean
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Kidney Injury - complications Acute renal failure Aerosols Aged Alveoli Amikacin Amikacin - administration & dosage Amikacin - adverse effects Amikacin - pharmacokinetics Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - pharmacokinetics Antimicrobial agents Area Under Curve Bacterial pneumonia Biological and medical sciences Bronchospasm Bronchus Care and treatment Critical Illness Dosage and administration Drug delivery Drug Delivery Systems Drug therapy Female Follow-Up Studies General pharmacology Gram-Negative Bacterial Infections - drug therapy Health aspects Health technology assessment Hemodiafiltration - methods Humans Inhalation Intravenous administration Lung Male Medical sciences Middle Aged Pharmaceutical technology. Pharmaceutical industry Pharmacokinetics Pharmacology. Drug treatments Pneumonia Pneumonia, Bacterial - drug therapy Pneumonia, Bacterial - microbiology Renal failure Renal function Respiration, Artificial Tissue Distribution Troughs Urine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!